Doctors question safety evidence as HHS weighs peptide compounding policy
Johns Hopkins and Harvard physicians say BPC-157 and GHK-Cu lack large human safety and efficacy trials even as regulatory momentum builds.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 24 09:05 ETSource: CNBC
The wire
- 01HHS is reportedly planning an interim access policy letting specialty pharmacies compound certain unapproved synthetic peptides supported by Health Secretary Robert F. Kennedy Jr., who called himself a fan on Joe Rogan's podcast in February 2026.
- 02Clinicians fielding patient questions get named sourcing: Caleb Alexander of Johns Hopkins cites absence of robust human evidence, while Harvard's Pieter Cohen points to BPC-157 and GHK-Cu as the compounds driving headlines.
- 03BPC-157 appears on the FDA list of injectables that may present significant safety risks; it has shown anti-inflammatory effects in animal and lab work but no large-scale human testing.
From the source
Read at cnbc.comFact vs. fiction: Doctors share whether peptides are safe and effective
From YouTube influencers to Reddit threads, the health and wellness side of the internet is full of talk about peptides.
